Bioinvent International Ab

Cancer Research Technology Limited

Monika Semmrich

Ingrid Teige

Linda Mårtensson

Björn Frendéus

Petra Holmkvist

Martin John Glennie

Aymen Al-Shamkhani

Stephen Beers

Juliet Gray

Described are novel antagonistic antibody molecules that specifically bind to TNFR2 on a target cell and thereby block TNF-α binding to TNFR2 and block TNFR2 signaling, wherein the antibody molecules also bind to Fc receptors via the Fc region. Also described is the use of such antibody molecules in treatment of cancer or infections caused by intracellular pathogens.

Antagonistic anti-TNFR2 antibodies

Described are novel anti-CTLA-4 antibody molecules and nucleotide sequences and expression vectors, such as viruses, encoding such antibody molecules. The novel antibody molecules are Treg depleting antibody molecules, and they have an improved depleting effect on CTLA-4 positive cells, such as Tregs, compared to ipilimumab. Described is also the use of such antibody molecules or nucleotide sequences or viruses in medicine, such as in the treatment of cancer, such as solid tumours.

Antibodies and nucleotide sequences, and uses thereof

Described are novel antibody molecules that specifically bind to TNFR2 on a target cell and thereby agonize TNFR2, but that do not block the ligand TNF-α from binding to the TNFR2. Also described is the use of such antibody molecules in medicine, i.a, in treatment of cancer or chronic inflammatory diseases.

Agonistic anti TNFR2 antibody molecules

Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.

Growing community of inventors

Malmö, Sweden

Monika Semmrich